COMPANY

Codagenix, Inc

HQ: Farmingdale, NY source · codagenix.com ↗ · Mid-Atlantic

Also known as Codagenix · 22 sources

Codagenix designs and develops vaccine candidates, working from the genetic sequence of the wild-type virus. From company website Source · Oct 12, 2026

Keywords: vaccine Influenza Respiratory Syncytial Virus Infections COVID-19 diarrhea Human Influenza Breast Neoplasms Neoplasm Metastasis SARS-CoV-2 COVI-VAC CodaLytic

Location: Farmingdale, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

8Trials (company is sponsor)14NIH grants

Timeline

Mar 28, 2023 Trial start Phase 1: Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children source ↗
Jan 15, 2023 Trial start Phase 1: A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer source ↗
Apr 14, 2022 Trial start Phase 1: Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19 source ↗
Apr 11, 2022 Trial start Phase 1: Intramuscular CodaVax-H1N1 in Healthy Adults source ↗
Dec 11, 2020 Trial start Phase 1: Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19 source ↗
Jul 10, 2020 Trial start Phase 1: Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers source ↗
May 7, 2019 Trial start Phase 1: Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray source ↗
Feb 21, 2017 Trial start Phase 1: Safety Study of Live Attenuated Influenza Vaccine, CodaVax source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT04919109	Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children	Phase 1	Terminated	Mar 28, 2023	Jun 26, 2025 (actual)
NCT05223179	Intramuscular CodaVax-H1N1 in Healthy Adults	Phase 1	Completed	Apr 11, 2022	Feb 9, 2024 (actual)
NCT05600582	A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer	Phase 1	Withdrawn	Jan 15, 2023	Sep 30, 2024 (estimated)
NCT05233826	Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19	Phase 1	Completed	Apr 14, 2022	Jul 21, 2022 (actual)
NCT04619628	Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19	Phase 1	Completed	Dec 11, 2020	Jun 26, 2021 (actual)
NCT04295070	Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers	Phase 1	Completed	Jul 10, 2020	Mar 6, 2021 (actual)
NCT04146623	Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray	Phase 1	Completed	May 7, 2019	Oct 11, 2020 (actual)
NCT03926416	Safety Study of Live Attenuated Influenza Vaccine, CodaVax	Phase 1	Completed	Feb 21, 2017	May 29, 2018 (actual)

NIH awards 14

Annual award amounts. Total $8.2M.

Jun 17, 2022 NIH award 5R44AI131756-05 FY2022: $809,351 awarded for that fiscal year; activity R44 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. A rationally-designed, live-attenuated RSV va source ↗
Jul 12, 2021 NIH award 5R44AI131756-04 FY2021: $665,459 awarded for that fiscal year; activity R44 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. A rationally-designed, live-attenuated RSV va source ↗
May 6, 2021 NIH award 1R44AI162404-01 FY2021: $999,267 awarded for that fiscal year; activity R44 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. Final Preclinical Testing and Formulation of source ↗
Jul 14, 2020 NIH award 3R44AI131756-03A1S1 FY2020: $1,716,496 awarded for that fiscal year; activity R44 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. Rapid generation and testing of live-at source ↗
Jul 2, 2020 NIH award 2R44AI131756-03A1 FY2020: $727,278 awarded for that fiscal year; activity R44 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. A rationally-designed, live-attenuated RSV source ↗
Jul 6, 2018 NIH award 5R44AI131756-02 FY2018: $744,622 awarded for that fiscal year; activity R44 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. Pre-clinical Commercialization of a Synthetic source ↗
Aug 15, 2017 NIH award 1R44AI131756-01 FY2017: $755,377 awarded for that fiscal year; activity R44 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. Pre-clinical Commercialization of a Synthetic source ↗
May 7, 2015 NIH award 5R41AI109911-02 FY2015: $296,388 awarded for that fiscal year; activity R41 (STTR); PI COLEMAN, JOHN ROBERT; recipient as written: CODAGENIX, INC., Farmingdale, NY. Live-attenuated ETEC Anti-Diarrhea Vaccin source ↗
May 5, 2015 NIH award 5R43AI109924-02 FY2015: $199,904 awarded for that fiscal year; activity R43 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. Ultra-low dose Influenza vaccines source ↗
Dec 9, 2014 NIH award 1R43AI116035-01 FY2015: $222,698 awarded for that fiscal year; activity R43 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. Balancing Immunogenicity of a Tetravalent Liv source ↗
Jun 12, 2014 NIH award 1R41AI109911-01A1 FY2014: $300,000 awarded for that fiscal year; activity R41 (STTR); PI COLEMAN, JOHN ROBERT; recipient as written: CODAGENIX, INC., Farmingdale, NY. Live-attenuated ETEC Anti-Diarrhea Vacc source ↗
May 27, 2014 NIH award 1R43AI109924-01 FY2014: $199,904 awarded for that fiscal year; activity R43 (SBIR); PI MUELLER, STEFFEN; recipient as written: CODAGENIX, INC., Farmingdale, NY. Ultra-low dose Influenza vaccines source ↗
May 17, 2013 NIH award 5R41AI100428-02 FY2013: $300,000 awarded for that fiscal year; activity R41 (STTR); PI WIMMER, ECKARD; recipient as written: CODAGENIX, INC., Farmingdale, NY. Rational Design of Live Attenuated Influenza A source ↗
Jun 15, 2012 NIH award 1R41AI100428-01 FY2012: $300,000 awarded for that fiscal year; activity R41 (STTR); PI WIMMER, ECKARD; recipient as written: CODAGENIX, INC., Farmingdale, NY. Rational Design of Live Attenuated Influenza A source ↗